Log in BPC-157 Rapid Pro InfiniWell 60 capsules $N/A (MSRP) Create account for pricing Already have an account
Jorsal A., Kistorp C., Holmager P., et al
Emerging evidence suggests potential hepatoprotective benefits, particularly in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease (NAFLD)
For eligible adults with clinically significant obesity, MHRA-approved options include semaglutide (Wegovy, assessed in NICE TA875) and tirzepatide (Mounjaro, assessed in NICE TA1026), both available through NHS pathways with appropriate clinical oversight
Semaglutide is expensive because its manufacturer, Novo Nordisk, owns the patent and subsequently has the exclusive right to market it until the patent expires